NCT06302140 2025-01-20
A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers
Viracta Therapeutics, Inc.
Phase 1 Terminated
Clinical Trials
15 trialsNCT03936959 2025-01-15
A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
NCT04270864 2024-10-18
PRIMO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Terminated
NCT02944864 2024-09-23
A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Terminated
NCT05128539 2024-03-26
A Study Explore JS001+JS002 in Patients With Advanced Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Terminated
NCT03444753 2022-05-23
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
Bristol-Myers Squibb
Phase 1 Terminated
NCT02992977 2020-06-02
Safety and Tolerability Study of AutoSynVaxâ„¢ Vaccine in Subjects With Advanced Cancer
Agenus Inc.
Phase 1 Terminated
NCT01394003 2019-01-18
A Study of LY2584702 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
NCT01347866 2018-10-29
Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
Pfizer
Phase 1 Terminated
NCT02671955 2018-03-27
A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer
Janssen Research & Development, LLC
Phase 1 Terminated
NCT01688791 2015-02-10
A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)
Endocyte
Phase 1 Terminated
NCT02136342 2014-10-21
Phase 1 Trial of Chlorogenic Acid in Patients With Advanced Cancer
ChineseAMS
Phase 1 Terminated
NCT00729833 2014-06-09
Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT00606879 2008-07-24
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
SGX Pharmaceuticals, Inc.
Phase 1 Terminated
NCT00607399 2008-07-24
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
SGX Pharmaceuticals, Inc.
Phase 1 Terminated